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Ms. A is a 33-year-old woman with a history of
depression and polysubstance use disorder who presented
to our hospital after transfer from another facility’s emer-
gency department after an intentional ﬂecainide overdose.
Her spouse heard a “thud” at approximately 5 AM on the day
of admission. He found her unconscious after she had
ingested 12 tablets of 150-mg ﬂecainide originally pre-
scribed to him. She was taken to another facility, where
she was found to be in a wide complex rhythm with a heart
rate of 63 (Figure 1) and blood pressure of 69/29. She was
given 1 L normal saline, started on 2 μg/kg/min of dobut-
amine, and electively intubated for airway protection in the
setting of altered mental status. Promptly after intubation,
she developed pulseless ventricular tachycardia (VT), which
necessitated initiation of advanced cardiac life support.
During this process, she received 11 ampules of sodium
bicarbonate, was started on intravenous (IV) isotonic sodium
bicarbonate at 150 cc/h, and given a 500-cc bolus of IV fat
emulsion. At this point, return of spontaneous circulation
was obtained, and the dobutamine infusion was stopped.
On arrival to our hospital, the patient was noted to be in an
irregular, wide complex tachycardia; otherwise her physical
examination was unremarkable. Result of laboratory studies
were notable for Na 160, K 3.0, HCO3 50, Cr 0.78, and iCal
0.77. Her blood gas values were pH 7.71, PaCO2 48, and PaO2
166 on 100% FiO2. During the early part of her course, she
received another 11 ampules of bicarbonate, and her
bicarbonate gtt was uptitrated to 300 cc/h. With this treat-
ment, her ECG stabilized to a junctional rhythm at 82 bpm
with intermittent runs of hemodynamically stable, slow VT.KEYWORDS Flecainide; Overdose; Arrhythmia; Extracorporeal membrane
oxygenation; Mechanical circulatory support
ABBREVIATIONS IV ¼ intravenous; VA-ECMO ¼ venoarterial
extracorporeal membrane oxygen; VT ¼ ventricular tachycardia
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During the day she became bradycardic, with heart rates
into the 40s, and was refractory to atropine. Despite the
development of atrial ﬁbrillation with frequent premature
ventricular complexes and an extremely prolonged QTc of
approximately 700 ms (Figure 2), her hemodynamic status
remained stable on vasopressin 0.04 units and phenyl-
ephrine 100 μg/min. Approximately 14 hours after arrival
to our hospital, she became more hemodynamically unsta-
ble and was refractory to multiple deﬁbrillations. Her
rhythm twice devolved into pulseless electrical activity
but recovered each time after advanced cardiac life support
to a monomorphic VT. At this time, the decision was made
to cannulate for venoarterial extracorporeal membrane
oxygen (VA-ECMO) support for refractory VT and shock.
During cannulation, her hemodynamics were supported
with a norepinephrine gtt and IV pushes of epinephrine.
Initial rates of VA-ECMO were approximately 4 L/min.
During her time on VA-ECMO, the patient received a total
of 8 units of packed red blood cells and 8 units of fresh
frozen plaza, believed secondary to blood loss. Approx-
imately 72 hours after cannulation, her ECG normalized to
normal sinus rhythm with ﬁrst-degree AV block and non-
speciﬁc ST/TW changes (Figure 3). She was weaned and
decannulated from VA-ECMO. Upon decannulation, she
was weaned off sedation and extubated uneventfully before
transfer to a psychiatric facility for further treatment of her
depression. Approximately 2 months after discharge, her
neurologic function is intact.
Discussion
We report the longest successful use of VA-ECMO for
treatment of ﬂecainide overdose and the ﬁrst successful use
of VA-ECMO for ﬂecainide overdose in the United States.
Flecainide is a class IC antiarrhythmic drug, a class of
medications whose overdose is associated with approxi-
mately 20% mortality.1 Flecainide causes rate-dependent
slowing of the fast sodium current INa during phase 0 of the
cardiac action potential as well as inhibition of the rectiﬁer
potassium current IKr during phase 3.
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KEY TEACHING POINTS
 Flecainide overdose is difﬁcult to treat because of
the drug’s high oral bioavailability (90%), high
volume of distribution, long half-life (up to 23
hours), poor ability to be dialyzed, lack of an
antidote, and rapid onset of shock and arrhythmias
(as early as 30 minutes after ingestion).
 Initial management consists of careful monitoring
of vital signs with admission to the intensive care
unit, telemetry, administration of activated
charcoal, repletion of electrolytes, aggressive use
of IV ﬂuids and hypertonic sodium bicarbonate,
and the potential use of IV fat emulsion.
 Flecainide overdose can rapidly cause arrhythmias
and shock, which if refractory to medications
(antiarrhythmics, vasopressors) and electricity
(pacing, cardioversion) will require mechanical
circulatory support, most commonly venoarterial
extracorporeal membrane oxygen (VA-ECMO). We
recommend early evaluation of the patient by the
ECMO team because VA-ECMO, even of sustained
duration, appears to be a lifesaving intervention
for refractory cardiogenic shock due to ﬂecainide
overdose.
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kg), long half- life (up to 23 hours), poor ability to be
dialyzed, lack of an antidote, and rapid onset of shock and
arrhythmias (as early as 30 minutes after ingestion).1,5,6
Flecainide overdose is relatively rare, and the literature on
its treatment is limited to animal studies and case reports.
Initial management consists of careful monitoring of vital
signs, telemetry, aggressive IV ﬂuids, repletion of electro-
lytes, and admission to the intensive care unit. Because of
ﬂecainide’s high oral bioavailability, treatment may include
gastric lavage if the patient presents within 1 hour of
ingestion and activated charcoal regardless of the time to
presentation.1,6 Our patient did not receive gastric lavage
because she presented to our hospital more than 1 hour after
ingestion. Multiple studies support the early and ample use
of hypertonic sodium bicarbonate,2,3,5,7 which has been
reported in doses up to 350 mEq5 for a goal pH of 7.5–
7.55 or a goal QRS width o160 ms.1 A high sodium
concentration is theorized to antagonize ﬂecainide at sodium
channels on cardiac myocytes.5 Flecainide is a weak base,
and alkalization of the blood may decrease the ionized form
of ﬂecainide, which binds sodium channels.2,7 Recent
literature supports the use of IV fat emulsion (100 mL or
1.5 mL/kg of 20% IV fat emulsion) to decrease the volume of
distribution of fat-soluble medications such as ﬂecainide.8Flecainide can induce rapid arrhythmias, particular bradyar-
rhythmias, heart block, VT, ventricular ﬁbrillation, and pulse-
less electrical activity.5,9 These rhythms may be refractory to
electrical cardioversion.8,10,11 Treatment options include atro-
pine or a pacemaker for bradyarrhythmias, although capture
may be difﬁcult.10,12,13 For tachyarrhythmias, there have been
reports of success with lidocaine for sustained VT, although
the theoretical risk of interaction between class IB and IC
agents remains high.14 Another report from Germany reported
success with amiodarone for treatment of refractory ventricular
ﬁbrillation,11 and a separate review suggested antitachycardia
treatment with a pacemaker or isoproterenol if needed.1
Because of ﬂecainide’s ability to cause both bradyarrhythmias
and tachyarrhythmias, clinicians should be cautious when
monitoring for therapeutic interventions causing overcompen-
sation (ie, bradyarrhythmia becoming a tachyarrhythmia and
vice versa).
Shock can develop rapidly in ﬂecainide overdose due to
chronotropic and inotropic incompetence.2,4 Use of vaso-
pressors such as phenylephrine is difﬁcult because of reﬂex
bradycardia. Use of inotropic agents may be limited by the
rate-dependent effect of ﬂecainide as well as the risk of
precipitating ventricular arrhythmias. There have been
reports of use of assist devices to support individuals through
ﬂecainide-induced cardiogenic shock. Timperley et al4 pub-
lished the ﬁrst and only successful use of an intra-aortic
balloon pump for a patient treated as having cardiogenic
shock from a myocardial infarction, which was diagnosed
after discharge as a ﬂecainide overdose. In the ﬁrst descrip-
tion of VA-ECMO for ﬂecainide overdose, Yasui et al15
showed that 10 hours of VA-ECMO lowered ﬂecainide
levels (peak 5.45 μg/mL) after ingestion of an unknown
quantity of medication. However, care was withdrawn after
the patient was found to have poor neurologic function. The
report argued for the use of VA-ECMO in shock to maintain
perfusion to the liver, which sustains ﬂecainide clearance.
The ﬁrst successful report using VA-ECMO was in 1999
from Australia, where VA-ECMO was used for 30 hours for
a 4-g ingestion.13 The patient survived to discharge with
normal neurologic function. In the second successful report,
also from Australia, VA-ECMO was used for 26 hours for a
6-g ingestion, and the authors argue that VA-ECMO time
436 hours is unlikely to be required.12 The use of VA-
ECMO in these reports was complicated by bleeding and
hematoma formation requiring blood products,12,13,15 similar
to our experience.
To our knowledge, this is the ﬁrst case report of VA-
ECMO time436 hours for treatment of ﬂecainide overdose
and the ﬁrst successful use of VA-ECMO for ﬂecainide
overdose in the United States. This reports shows that a
longer duration of VA-ECMO (up to 72 hours) may be
required for ﬂecainide overdose. A longer duration of VA-
ECMO can lead to survival with resulting normal neurologic
function.
Figure 1 ECG on presentation.
139Mandawat et al VA-ECMO Treatment of Flecainide OverdoseIn treatment of ﬂecainide overdose, our review of the
literature suggests that initial care should include careful
monitoring of vital signs with admission to the intensive
care unit, administration of activated charcoal, repletion ofFigure 2 ECG before venoarterial extracorporealelectrolytes, aggressive use of IV ﬂuids and hypertonic
sodium bicarbonate, and the potential use of IV fat
emulsion. Flecainide overdose can rapidly cause arrhyth-
mias and shock, which if refractory to medications (anti-membrane oxygen (VA-ECMO) cannulation.
Figure 3 ECG before venoarterial extracorporeal membrane oxygen (VA-ECMO) decannulation.
Heart Rhythm Case Reports, Vol 1, No 3, May 2015140arrhythmics, vasopressors) and electricity (pacing, cardio-
version) will require mechanical circulatory support, most
commonly VA-ECMO. We recommend early evaluation of
the patient by the ECMO team because VA-ECMO, even
of sustained duration, appears to be a lifesaving interven-
tion for refractory cardiogenic shock due to ﬂecainide
overdose.
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